Copyright
©The Author(s) 2015.
World J Gastroenterol. Feb 14, 2015; 21(6): 1907-1914
Published online Feb 14, 2015. doi: 10.3748/wjg.v21.i6.1907
Published online Feb 14, 2015. doi: 10.3748/wjg.v21.i6.1907
Figure 5 Survival free of antibodies to infliximab and loss of response.
A: ATI development in cases vs controls; B: Secondary LOR in cases vs controls. The asterisk shows that five of the controls experienced secondary LOR at a time-point comparable to the double negative event. ATI: Antibodies to infliximab; LOR: Loss of response.
- Citation: Ungar B, Anafy A, Yanai H, Ron Y, Yavzori M, Picard O, Fudim E, Loebstein R, Kopylov U, Chowers Y, Dotan I, Eliakim R, Ben-Horin S. Significance of low level infliximab in the absence of anti-infliximab antibodies. World J Gastroenterol 2015; 21(6): 1907-1914
- URL: https://www.wjgnet.com/1007-9327/full/v21/i6/1907.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i6.1907